the peptide is sensitive to mechanical stress
Combination Therapy Use of Semaglutide in Patients with Type 2 Diabetes Mellitus Combination with Metformin and/or Thiazolidinediones In a 56-week, double-blind trial (NCT01930188), 1231 patients with type 2 diabetes mellitus were randomized to semaglutide 0.5 mg once weekly, semaglutide 1 mg once weekly, or sitagliptin 100 mg once daily, all in combination with metformin (94%) and/or thiazolidinediones (6%)
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and decreased appetite
If you experience injection site reactions or systemic symptoms, spacing the injections may help you identify which intervention caused the symptoms, though this does not improve safety or efficacy
This triple action leads to more profound metabolic effects, including greater weight loss, better blood sugar control, and enhanced fat burning